Multicenter database for pancreatic solid pseudopapillary neoplasm
The Construction and Maintenance of A Real World Study Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas
Fudan University · NCT07183280
This project will collect clinical, pathology, treatment, and follow-up data from people with pancreatic solid pseudopapillary neoplasm to build a multicenter database to help guide care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | Fudan University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai, Special Administrative Region) |
| Trial ID | NCT07183280 on ClinicalTrials.gov |
What this trial studies
This observational multicenter effort will systematically collect real-world clinical, pathological, imaging, surgical, and follow-up data from patients with pathologically or cytologically confirmed pancreatic solid pseudopapillary neoplasm (SPN). Patients of any age and gender who meet diagnostic criteria and agree to follow-up are eligible, with Shanghai Cancer Center serving as the lead site for data contribution. The database will aggregate information on demographics, tumor characteristics, treatments (including surgery), and outcomes to generate real-world evidence for clinical and translational research. Analyses will examine natural history, prognostic features, patterns of care, and factors linked to recurrence or metastasis to inform management and future studies.
Who should consider this trial
Good fit: Ideal candidates are people of any age with pathology- or cytology-confirmed pancreatic SPN who can provide clinical records and comply with scheduled follow-up at the participating center.
Not a fit: Patients without a confirmed pancreatic SPN, those with non-pancreatic primary tumors, or those unable to provide follow-up information are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the database could improve understanding of long-term outcomes and help clinicians identify high-risk patients and better tailor surgical and follow-up strategies.
How similar studies have performed: Several retrospective multicenter case series in Asia have reported clinical features and outcomes of SPN, but comprehensive prospective real-world databases for this tumor type remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * No restrictions on age, gender, or performance status; * Pathologically/cytologically confirmed SPN; * Compliance with follow-up requirements; Exclusion Criteria: * Non-neoplastic pancreatic lesions; * Non-pancreatic primary tumors; * Non-compliance with follow-up;
Where this trial is running
Shanghai, Special Administrative Region
- Shanghai Cancer Center — Shanghai, Special Administrative Region, China (RECRUITING)
Study contacts
- Principal investigator: Guopei Luo — Shanghai Cancer Center
- Study coordinator: Huanyu Xia, MD
- Email: xiahuanyu@fudanpci.org
- Phone: +86 2164175590
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Solid Pseudopapillary Neoplasm of the Pancreas, Multicenter real-world database